Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.50), in-line with the analyst estimate of ($0.50).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Array Technologies (ARRY) PT Lowered to $10 at Jefferies, 'Playing Offense Amid Preferred Anxiety'